Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

Pharmacogenetics and genomics - 1 Apr 2014

Johnson Daniel H, Venuto Charles, Ritchie Marylyn D, Morse Gene D, Daar Eric S, McLaren Paul J, Haas David W

Abstract excerpt

BACKGROUND: Atazanavir-associated hyperbilirubinemia can cause premature discontinuation of atazanavir and avoidance of its initial prescription. We used genomewide genotyping and clinical data to characterize determinants of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. METHODS: Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bilirubin

Share to Glucuronosyltransferase

Share to HIV Protease Inhibitors

Share to Hyperbilirubinemia

Share to Oligopeptides

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 24557078
DOI: 10.1097/FPC.0000000000000034
PMCID: PMC4059003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.PMID 24557078Read ↗

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Semantic proximity Read ↗

Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.Semantic proximity Read ↗

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.Semantic proximity Read ↗

Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.Semantic proximity Read ↗

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.Semantic proximity Read ↗

A population pharmacokinetic-pharmacogenetic analysis of atazanavir.Semantic proximity Read ↗

Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.Semantic proximity Read ↗

Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.Semantic proximity Read ↗

Pharmacogenetics of Gilbert's syndrome.Semantic proximity Read ↗

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.